(Beijing and Hong Kong, November 20th 2017)– Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”, SEHK Stock Code: 0950) and Beijing Shenogen Pharma Group Ltd. (“Shenogen”) entered into a collaboration agreement to jointly develop and commercialize in China a combination product that is composed of their respective compounds, ZKAB001 (PD-L1 monoclonal antibody) and icaritin, for treatment of late stage cancers.

China Oncology Focus Limited, an Affiliate of Lee’s Pharm, is currently developing PD-L1 monoclonal antibody licensed from Sorrento Therapeutics, Inc. of USA for the treatment of late stage cancers. Shenogen is currently developing icaritin, a small molecule for treatment of late stage HCC.  Icaritin has demonstrated synergistic effects with PD-L1 monoclonal antibody in animal models.  Both Lee’s Pharm and Shenogen believe by combining these two compounds in treating late stage cancer patients, there will be an enhanced efficacy than either product alone.

“Lee’s Pharm is looking forward to further collaborating with Shenogen in addition to the ongoing collaboration regarding the combination of Pexa-Vec with icaritin” Dr. Benjamin Li, CEO of Lee’s Pharm said, “to bring more benefits to cancer patients in China”.  Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd, further expressed his enthusiasm and confidence about collaborating with Lee’s Pharm.

About ZKAB001 (PD-L1 monoclonal antibody):

ZKAB001 is a fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) （STI-A1014）, an immune checkpoint inhibitor that binds to the human programmed death-ligand 1 (PD-L1) protein and blocks the interaction of PD-L1 protein with its receptor PD-1, then suppressing the inhibition of PD-1/PD-L1 signal to T cells and enhancing the killing effect of T cells on tumors. This antibody also kills cancer cells through traditional antibody-dependent cell-mediated cytotoxicity (ADCC). That is, the antibody variable region (Fv) combining with PD-L1 on cancer cells and the antigen crystal region (Fc) binding to immune cells such as NK cells, enables immune cells to directly kill cancer cells and further strengthens anti-tumor effect of the antibody. It is licensed from Sorrento Therapeutics, Inc. (NASDAQ： SRNE).

About Icaritin: 

Icaritin is a purified single compound derived from a Chinese herb Epimedium (hornygoat weed). Icaritin is currently in Phase 3 clinical studies for HCC patients in China.

About Lee’s Pharm: 

Lee's Pharmaceutical Holdings Limited is a research-based, biopharmaceutical company listed in Hong Kong with over 20 years of operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets 15 products in China. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.  Additional information is available at http://www.leespharm.com

About Beijing Shenogen Pharma Group Ltd.:

Beijing Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. The Company possesses robust intellectual property rights around novel targets for anticancer therapies.  Additional information is available at http://www.shenogen.com

About Beijing Shenogen Pharma Group Ltd (“Shenogen Pharma”)

Beijing Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. The Company possesses robust intellectual property rights around novel targets for anticancer therapies.  Additional information is available at http://www.shenogen.com

About Lee’s Pharmaceutical Holdings Ltd. (“Lee’s Pharm”)

Lee's Pharmaceutical Holdings Limited is a research-based, biopharmaceutical company listed in Hong Kong with over 20 years of operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets 15 products in China. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.  Additional information is available at http://www.leespharm.com

About China Oncology Focus Limited (“COF”)

COF is a 65%-owned subsidiary of Lee’s Pharmaceutical Holdings Limited and is a drug development company specialized in oncology disease area. COF is currently developing three assets, namely PD-L1, TG02 and Glufosfamide. PD-L1 is a human monoclonal antibody against programmed cell death 1 ligand 1 and its development is to help cancer patient’s own immune system to fight the disease. TG02 is a unique, oral multi-kinase inhibitor and its development will initially focus on the treatment of hematologic malignancies including multiple myeloma. Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects.  It is currently being evaluated in a pivotal Phase 3 international randomized trial, for the second-line treatment of patients with pancreatic cancer. The Phase 3 study in China is expected to be commenced by 1H2018.

Forward-Looking Statement for Lee’s Pharm

The performance and the results of operation of Lee’s Pharm during the past years are historical in nature and past performance can be no guarantee of future results of the Lee’s Pharm. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee’s Pharm nor the Directors, employees or agents of Lee’s Pharm assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.

Lee's Pharm

Vivian Fung

Licensing & Regulatory Manager

Tel: 852.23141282 or info@leespharm.com

Contact Information:

Shenogen Pharma Group

Yuqing He

Business Development Manager

Tel: 86(10)80709213x1890 or yuqing.he@shenogen.com